About
GutGutGoose develops personalized probiotics and microbiome-testing services for consumers in the United States and Australia. Customers submit at-home stool samples; the company sequences their microbiome, models which strains can colonize, formulates a tailored probiotic, and retests later, differentiating it from generic supplements through strain-level personalization and outcome verification.
Market
GutGutGoose competes in the direct-to-consumer precision gut-health market, combining microbiome sequencing, personalized probiotic supplementation, and ongoing measurement. It positions itself against generic probiotics and more basic microbiome-reporting services through mechanistic metabolic modeling, simulated strain-selection, custom compounding, and 90-day retesting that links the intervention to observed outcomes. Its broader strategic differentiation is a data flywheel: each customer contributes a baseline gut profile, a defined probiotic intervention, and a measured follow-up result.
GutGutGoose primarily targets health-conscious adults aged 18+ in the US and Australia who want to improve gut health, particularly consumers dissatisfied with generic, one-size-fits-all probiotics or experiencing issues such as bloating and digestive irregularity. Its secondary audience includes clinics and research collaborators interested in microbiome testing, personalized formulas, and longitudinal gut-health data.
At a Glance
Problem
GutGutGoose is addressing the difficulty of detecting disease risk early enough and with sufficient biological specificity. The company’s stated killer use case is strain-level metabolic modelling of the gut to catch disease decades early, using the gut—and even “poop’s data”—as a source of actionable information. The research supplied does not quantify the economic cost of late diagnosis or identify a particular disease, but the implied pain is delayed detection and less personalized treatment.
Product / Service
GutGutGoose describes its offering as “AI training infrastructure via custom probiotics.” Its approach combines personalized probiotics with a mechanistic algorithm and strain-level modelling of gut metabolism. The intended benefit is to use an individual’s gut biology to design more tailored probiotic interventions while generating signals that may support much earlier disease detection. The available evidence does not specify the exact customer delivery model, testing workflow, or pricing.
Market
The company sits at the intersection of biotech, personalized health, and wellness, with its YC profile categorizing it under Biotech and Personalization, Health & Wellness. It appears to compete in the emerging market for microbiome-based diagnostics and personalized probiotics, although no direct competitors are identified in the supplied research.
GutGutGoose is listed as an active Summer 2026 YC company in San Francisco and shows two jobs on its public company profile. The available evidence establishes early company activity but does not disclose revenue, customers, clinical validation, or fundraising, so its revenue status cannot be determined from the research provided.
Founders & Leadership
Funding History
Y Combinator
Recent News
GutGutGoose published a comparison guide explaining how to evaluate personalized probiotics, including at-home microbiome testing and verified colonization. The article positions its own Australian-built offering as backed by Y Combinator and LuminaX HealthTech.
GutGutGoose announced its Y Combinator launch, describing a personalized probiotic designed to improve over time while generating microbiome data. The launch highlights the company’s model of matching probiotics to an individual gut rather than using a universal formula.
The University of Southern Queensland profiled co-founders Anis Mihrshahi and Leon Mojarrabi after GutGutGoose was accepted into Y Combinator. The article discusses the company’s personalized-probiotic approach, validated prediction engine, upcoming beta phase, and plans for growth in Silicon Valley.
SynBioBeta reported that GutGutGoose joined Y Combinator and secured US$500,000 to develop personalized probiotics using AI, microbiome sequencing, and metabolic modeling. The post identifies Anis Mihrshahi and Leon Mojarrabi as the founders.
Startup Daily reported that Queensland startup GutGutGoose was selected for the latest Y Combinator program and secured approximately A$700,000, equivalent to US$500,000, through the accelerator.
Business News Australia reported GutGutGoose’s acceptance into Y Combinator and its US$500,000 funding. The company plans to use AI, microbiome sequencing, and computational modeling to create probiotic formulations tailored to individual biology, with a larger beta phase planned after its initial alpha cohort.
LuminaX HealthTech announced that its 2025 alumnus GutGutGoose had been accepted into Y Combinator. The announcement highlights the accelerator’s US$500,000 seed funding, the founders’ relocation to San Francisco, and the company’s pharmaceutical-grade, microbiome-matched probiotics.
Active Roles
1Business Model
GutGutGoose sells subscription-based at-home gut testing and personalized probiotic plans. Its website lists launch pricing of $50 per month for advanced gut testing and $200 per month for personalized probiotics, with recurring retesting and analysis supporting ongoing subscriptions.